Bambusa Therapeutics, Inc. (NASDAQ:BBTX – Get Free Report) Director Ra Capital Management, L.P. bought 2,500,000 shares of the company’s stock in a transaction dated Monday, November 2nd. The stock was bought at an average cost of $16.00 per share, for a total transaction of $40,000,000.00. Following the acquisition, the director owned 5,933,787 shares of the […]

Bambusa Therapeutics, Inc. (NASDAQ:BBTX – Get Free Report) major shareholder Salvia Investment Gmbh bought 375,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The shares were acquired at an average price of $16.00 per share, with a total value of $6,000,000.00. Following the completion of the transaction, the insider […]

Lycia Therapeutics, Inc. (NASDAQ:LYCA – Get Free Report) major shareholder Venrock Healthcare Capital Par purchased 1,000 shares of the stock in a transaction that occurred on Thursday, October 29th. The stock was bought at an average cost of $26.33 per share, with a total value of $26,330.00. Following the acquisition, the insider owned 6,841,233 shares […]

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) Director Dennis Podlesak sold 8,000 shares of the firm’s stock in a transaction on Thursday, October 29th. The stock was sold at an average price of $14.21, for a total transaction of $113,680.00. Following the sale, the director owned 239,763 shares in the company, valued at approximately […]

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Monday, October 19th. The stock was sold at an average price of $543.32, for a total value of $5,161,540.00. Following the transaction, the chief executive officer owned 324,443 shares of the company’s stock, […]